The importance of these discoveries relies on the fact that we can modulate the SCLC phenotypes thanks to the administration of drugs such as LSD-1 or EZH2 inhibitor, as we reported earlier, with the aim to augment the sensitivity of patients with SCLC to ICI [205]. Here, EZH2 is linked to small cell lung carcinoma.